JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.

Complement, Coagulation & FcRn

Complement, coagulation and FcRn antibodies act on plasma protein cascades and on recycling of immunoglobulin G (IgG). Eculizumab, ravulizumab and pozelimab bind complement component C5 and block formation of the membrane attack complex. Sutimlimab inhibits C1s, the serine protease that initiates the classical complement pathway. Emicizumab bridges activated factor IX and factor X, while concizumab and marstacimab bind tissue factor pathway inhibitor (TFPI). Nipocalimab and rozanolixizumab block the neonatal Fc receptor (FcRn) and are used to study IgG half-life and clearance.

Cat. No.

AT0396

CAS No.

3008610-21-4

Cenvacibart

Cenvacibart is a monoclonal antibody designed to inhibit coagulation factor XI (F11), a key protein in the coagulation cascade. By targeting and blocking the activity of factor XI, Cenvacibart effectively reduces thrombus formation. This antibody is particularly valuable in the study of thrombotic disorders, offering a promising tool for researchers exploring the mechanisms and potential treatments of these conditions.

In stock View Details

1 mg

$450.00

5 mg

$1,400.00

All 3 sizes

Complement, Coagulation & FcRn

Cenvacibart